Clinical Development


Oprozomib is an orally-administered epoxyketone proteasome inhibitor, similar to, but distinct from carfilzomib. Oprozomib is currently being studied in a number of trials, including several ongoing Phase 1 and Phase 2 studies in multiple myeloma, Waldenstrom’s macroglobulinemia, and advanced liver cancer.

Oprozomib recently received orphan drug designation for the treatment of Waldenstrom’s macroglobulinemia and multiple myeloma.